机译:单孕易含素治疗 - Na'Ve患者的慢性淋巴细胞白血病患者的单孕酮治疗方案:第3期研究的交叉试验比较
Medical University of Lodz Copernicus Memorial HospitalLodz Poland;
The University of Texas MD Anderson Cancer CenterHouston Texas;
ASST Grande Ospedale Metropolitano NiguardaMilan Italy;
Wilmot Cancer Institute University of Rochester Cancer CenterRochester New York;
Tom Baker Cancer CentreUniversity of CalgaryCalgary Alberta Canada;
Rabin Medical Center Beilinson Hospital and Sackler Faculty of MedicineTel Aviv UniversityTel Aviv;
The Leeds Teaching Hospitals St. James's Institute of OncologyLeeds UK;
North Shore HospitalAuckland New Zealand;
School of Public Health Silesian Medical UniversityKatowice Poland;
King's College Hospital NHS Foundation TrustLondon UK;
Royal Bournemouth HospitalBournemouth UK;
Stanford University School of MedicineStanford California;
St. Vincent's Hospital University of MelbourneMelbourne Australia;
Department of Translational MedicineAmedeo Avogadro University of Eastern PiedmontNovara Italy;
Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of;
Norton Cancer InstituteLouisville Kentucky;
Hospital de la Santa Creu i Sant PauBarcelona Spain;
Princess Alexandra HospitalBrisbane Australia;
Sarah Cannon Research Institute/Tennessee OncologyNashville Tennessee;
Barts Cancer Institute Queen Mary University of LondonLondon UK;
Pharmacyclics LLC an AbbVie CompanySunnyvale California;
Pharmacyclics LLC an AbbVie CompanySunnyvale California;
Pharmacyclics LLC an AbbVie CompanySunnyvale California;
Pharmacyclics LLC an AbbVie CompanySunnyvale California;
University of California San DiegoMoores Cancer CenterLa Jolla California;
Università Vita‐Salute San Raffaele and IRCCS Istituto Scientifico San RaffaeleMilan Italy;
机译:单孕易含素治疗 - Na'Ve患者的慢性淋巴细胞白血病患者的单孕酮治疗方案:第3期研究的交叉试验比较
机译:CLL2-BIG - 一种新型的弯曲蛋白治疗方案,然后是GA101和Ibrutinib,慢性淋巴细胞白血病(CLL)患者中的伊布勒替尼和GA101维持:II期 - 试验的结果
机译:基于伊布勒替尼(PCI-32765)的随机期III研究与疗法对齐。 标准氟拉西滨,环磷酰胺和Rituximab(FCR)化疗疗效在未处理的慢性淋巴细胞白血病(CLL)中的患者(CLL):ECOG-acrm癌症研究组的试验(E1912)
机译:慢性淋巴细胞白血病与外显子组序列和机器学习的交叉验证和交叉研究验证
机译:激酶靶向疗法在慢性淋巴细胞性白血病中:获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
机译:单药依鲁替尼与化学免疫疗法治疗初治慢性淋巴细胞白血病的患者:3期研究的交叉试验比较
机译:单孕素易含素治疗治疗方案 - 慢性淋巴细胞白血病患者:第3期研究的交叉试验比较